Fundraising Fox
/Companies
Sign in

Estrigenix Therapeutics

Wauwatosa, US · Delaware corporation · 1 known investors

Find your way into Estrigenix Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

118 people can intro you to Victoria

Ask Gareth MacLeod to introduce you to Victoria R. Zellmer

You →Gareth · together at Invert →Victoria

Sign up to find every way you can get introduced to Estrigenix Therapeutics

  • Your email: who you already know at Estrigenix Therapeutics, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Estrigenix Therapeutics team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Estrigenix Therapeutics is a pharmaceutical company developing first-in-class therapeutics based on estrogen biology to treat and prevent hot flashes and dementia in post-menopausal women. It aims to license its lead compounds to pharmaceutical companies after phase 2 clinical trials, offering menopause symptom relief without the breast cancer and stroke risks of traditional hormone replacement therapy.

BiotechDigital HealthFemTechHealthtech

Founders & leadership

BD
Bill DonaldsonChief Executive Officer
VR
Victoria R. ZellmerChief Executive OfficerVictoria Zellmer has worked in translational research and life sciences research programs, with expertise in project management, regulatory compliance, and business development. She is CEO of Estrigenix Therapeutics, which develops estrogen-based therapeutics for menopausal symptoms and age-related conditions.
DS
Daniel SemVice President of Business Development
KF
Karyn FrickChief Scientific Officer
PS
Patricia SchellerExecutive Chair

Investors · 1

TalentsreportedMequon

How we know: offering press articles · funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$1M disclosed across 1 round · 2026

▶$1MraisedJul 2026 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel SemExecutive Officer, Director
  • William DonaldsonExecutive Officer, Director
  • Karyn FrickExecutive Officer
  • Patricia SchellerDirector
  • Victoria ZellmerExecutive Officer
Offering amount
$2M
Amount sold
$1M
Minimum investment
$150K
Proceeds to insiders
$250K
First sale
Jul 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

Generate BiomedicinesGenerate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering. The company creates new drugs on demand across diverse biologic modalities for immunology, oncology, infectious disease, and vaccines.
IRIS MEDICINEIris Medicine is an early-stage biotech developing RNA therapies based on its small binding RNA (sbRNA) platform, which uses cooperative RNAi binding to selectively silence mutant genes carrying expanded pathologic repeat sequences while preserving healthy alleles. Its lead programs target repeat expansion disorders including Huntington's Disease, C9orf72 ALS, and the Spinocerebellar Ataxias.

Companies working in the same space as Estrigenix Therapeutics.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2022$299.1K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Estrigenix Therapeutics Announces Series Seed Financing to Advance ERβ Platform Across Women's Health and Neurodegenerative Diseases - Estrigenixestrigenix.com · Jul 2026Estrigenix Therapeutics Raises $2M in Seed Fundingfinsmes.com · Jul 2026

Frequently asked questions

What does Estrigenix Therapeutics do?
Estrigenix Therapeutics is a pharmaceutical company developing first-in-class therapeutics based on estrogen biology to treat and prevent hot flashes and dementia in post-menopausal women. It aims to license its lead compounds to pharmaceutical companies after phase 2 clinical trials, offering menopause symptom relief without the breast cancer and stroke risks of traditional hormone replacement therapy.
Who are Estrigenix Therapeutics's investors?
Estrigenix Therapeutics's investors include Talents.
How much funding has Estrigenix Therapeutics raised?
Estrigenix Therapeutics has disclosed $1M raised across 1 round.
Where is Estrigenix Therapeutics headquartered?
Estrigenix Therapeutics is headquartered in Wauwatosa, US.